Molecular Assay for Drug Resistant TB Testing

PHO believes that the following procurement qualifies as a sole source or single source procurement. The purpose of this Advanced Contract Award Notice (ACAN) is to determine if there are other proponents capable of meeting the requirements of the procurement for the following supplies for PHO.

Vendor: Becton Dickinson Canada Inc
Product: BD Max MDR-TB Assay
Purpose: A Health Canada approved assay for the detection of drug resistant Mycobacterium tuberculosis. The drug resistance targets sought as part of this assay are for isoniazid and rifampin.

PHO has a requirement a commercial Health Canada approved molecular assay for detection of drug resistant Mycobacterium tuberculosis, with drug resistance targets of isoniazid and rifampin. Recent changes to the Canadian Tuberculosis Standards require a test with a short turnaround time to determine prompt treatment for individuals with M. tuberculosis detected by molecular assays. As such, PHO requires supply of an assay which is capable of detecting multidrug resistant tuberculosis from clinical specimens, as well as culture isolates.
PHO believes that the BD MAX MDR-TB Assay is the only commercial Health Canada approved assay for this use capable of detecting isoniazid and rifampin resistant M. tuberculosis.

PHO intends to award a 5 year term contract (comprised of 2 firm years and 3 one-year options) to Becton Dickinson for the products described above.

This request does not constitute a call for tenders.